Navigation Links
New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
Date:4/3/2008

SCOTTSDALE, Ariz., April 3, 2008 /PRNewswire/ -- In this report, entitled "MedPredict Thought Leader Insight & Analysis: Pharmacotherapies for Alcoholism," physician experts discuss the key controversies surrounding development of drugs for alcoholism, and why they think the biopharmaceutical industry is underestimating the size of this market.

According to this physician panel, there are a number of factors stymieing biopharmaceutical companies, including the lackluster commercial performance of naltrexone and acamprosate, a lack of clear FDA guidance on trial design and resulting indications, the stigma associated with alcoholism and associated corporate image risks, and the tremendous fear of product liability litigation. The general corporate perception is that drugs for alcoholism won't be reimbursable, and many of the people who come in for treatment will not be able to afford medicine.

"An analogy would be to attempt to forecast the size of the antidepressant market before the availability of Prozac," according to Dr. Jeff Berk, the report's principal author. "While competitive intensity in the alcoholism field has been low by traditional measures, it is clearly now emerging. We expect to see tremendous growth after the first successful product launches into the primary care physician's office."
Also addressed by MedPredict's panel:

-- Unmet needs from the patient, specialist, general practitioner,

3rd-party payer and societal perspective,

-- Habits & practices of specialists, general practitioners and

non-medical treaters,

-- Hurdles preventing increased diagnosis and treatment of alcoholism,

particularly in the community setting, and a commercialization model

that Pharma can follow to overcome these,

-- Changing paradigms in primary and secondary clinical trial endpoints

and alcoholism trial designs, and

-- New screening tools and behavioral diagnostic instruments.

Drugs/classes mentioned in this report: ReVia (naltrexone); Vivitrol (extended release injectable naltrexone; Alkermes / Cephalon); Campral (acamprosate; Forest); Antabuse (disulfiram); gabapentin (generic); Topamax (topiramate; Ortho-McNeil); Prometa (flumazanil / gabapentin / hydroyzine; Hythiam); glutamatergic; non-NMDA; kainate; AMPA; CB-1; Acomplia (rimonabant; Sanofi-Aventis); SSRI; dopaminergic; Seroquel (quetiapine; AstraZeneca); NPY; NK; CRH.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
2. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
Breaking Biology News(10 mins):